Currently, an open-label phase I/II study evaluates OTX-2002 safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity as a single agent and in combination with the standard of care in patients with hepatocellular carcinoma or other solid cancers related to the MYC oncogene (NCT05497453) [306]. Here, MYC is linked to hepatocellular carcinoma.